Abstract
α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Graphical Abstract
Current Bioactive Compounds
Title:Antiedematogenic Effect of α-Phellandrene in Animal Models
Volume: 12 Issue: 2
Author(s): Hálmisson D.S. Siqueira, Benedito P.S. Neto, Damião P. Sousa, Bruno S. Gomes, Francisco V.M. Cunha and Francisco A. Oliveira
Affiliation:
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Abstract: α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Export Options
About this article
Cite this article as:
D.S. Siqueira Hálmisson, P.S. Neto Benedito, P. Sousa Damião, S. Gomes Bruno, V.M. Cunha Francisco and A. Oliveira Francisco, Antiedematogenic Effect of α-Phellandrene in Animal Models, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/1573407212666160210231052
DOI https://dx.doi.org/10.2174/1573407212666160210231052 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Activation of p53 by Specific Agents in Potential Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Cutaneous Larva Migrans
Recent Patents on Inflammation & Allergy Drug Discovery New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry Radiopharmaceuticals, Drug Development and Pharmaceutical Regulations in Europe
Current Radiopharmaceuticals Motility Disorders, Functional Gastrointestinal Disorders, Inflammatory Bowel Disease and Cardiac Rhythm Disturbances - Is there a Link? Review of Literature
Current Drug Targets Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Assessment of Platelet Activation in Antiplatelet Drug Development
Current Medicinal Chemistry Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?
Current Gene Therapy Measurement of Antioxidant Activity and Antioxidant Compounds under Versatile Extraction Conditions: II. The Immuno-Biochemical Antioxidant Properties of Black Sour Cherry (Prunus cerasus) Extracts
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin
Recent Patents on Biotechnology The Therapeutic Potential of 4-1BB (CD137) in Cancer
Current Cancer Drug Targets Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Biomarkers Downstream of RAS: A Search for Robust Transcriptional Targets
Current Cancer Drug Targets Macrolides in Community-Acquired Pneumonia: The Importance of the Non-Antimicrobial Effect
Current Respiratory Medicine Reviews Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Computationally Probing Drug-Protein Interactions Via Support Vector Machine
Letters in Drug Design & Discovery 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma
Endocrine, Metabolic & Immune Disorders - Drug Targets